一例由于使用Ipilimumab-Nivolumab联合治疗引起免疫相关不良事件的转移性肾细胞癌伴关节炎和结肠炎的病例。
[A Case of Metastatic Renal Cell Carcinoma with Arthritis and Colitis Due to Immune-Related Adverse Events During Ipilimumab-Nivolumab Combination Therapy].
发表日期:2023 Aug
作者:
Moe Toyoshima, Daiki Ikarashi, Hiroyuki Tsuboi, Makoto Moriwaka, Shinji Tamada, Tomohiko Matsuura, Shigekatsu Maekawa, Renpei Kato, Mitsugu Kanehira, Ryo Takata, Jun Sugimura, Wataru Obara
来源:
Arthritis & Rheumatology
摘要:
一名73岁患有肾细胞癌的男性患者在我们中心接受了左侧开放式根治性肾切除术。病理诊断为Fuhrman 2级,pT3a期,透明细胞型肾癌。手术后9个月的随访计算机断层扫描(CT)显示出肺转移灶。患者开始接受ipilimumab和nivolumab联合治疗,但在两个疗程后,他出现了关节痛和膝关节肿胀。此外,他几乎同时出现腹泻,导致中断ipilimumab和nivolumab治疗。我们诊断出免疫相关不良事件(irAE)引起的关节炎和结肠炎,并开始使用类固醇治疗并进行康复。患者的病情显著改善,三个月治疗中断后可以继续使用nivolumab治疗。
A 73-year-old man with renal cell carcinoma underwent a left-sided open radical nephrectomy at our center. The pathological diagnosis was Fuhrman Grade 2, stage pT3a, clear cell renal cell carcinoma. A follow-up computed tomography (CT) scan revealed lung metastases 9 months after the surgery. The patient was started on ipilimumab with nivolumab combination therapy; however, after two cycles of administration, he developed arthralgia and swelling of the knee. Furthermore, he developed diarrhea almost simultaneously, resulting in the interruption of the ipilimumab plus nivolumab treatment. We diagnosed arthritis and colitis with immune-related adverse events (irAE) and initiated steroid therapy with rehabilitation. His condition improved dramatically, and nivolumab treatment could be resumed after 3 months of treatment interruption.